Verastem Oncology
117 Kendrick Street
Suite 500
Needham
MA
02494
United States
Tel: (718) 292-4200
Website: http://www.verastem.com/
Email: info@verastem.com
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
Founded: 2010
425 articles about Verastem Oncology
-
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the AACR 2020 Virtual Annual Meeting I
4/27/2020
Verastem, Inc. announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors.
-
Verastem Oncology Appoints John H. Johnson to its Board of Directors
4/23/2020
Verastem, Inc., a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced that it has appointed John H. Johnson to its Board of Directors.
-
Verastem Oncology Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
4/21/2020
Verastem, Inc. (NASDAQ: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that in light of public health and safety precautions related to COVID-19, including restrictions on in-person gatherings, the Company’s 2020 annual meeting of stockholders will be changed from an in-person meeting to a virtual-only meeting
-
Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors
4/20/2020
Conference Call to Discuss Preliminary Clinical Data Being Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I
-
Verastem Oncology Announces Presentation of Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors at the American Association for Cancer Research 2020 Virtual Annual Meeting I
4/13/2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that an abstract highlighting preliminary results from the ongoing investigator-initiated clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 7, 2020
4/7/2020
Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 127,500 shares of its common stock to nine new employees.
-
Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results
3/11/2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today reported financial results for the three months and full-year ended December 31, 2019, and provided an overview of recent corporate highlights.
-
Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs
2/28/2020
Feb. 28, 2020 11:05 UTC Transformative Initiative Expected to Accelerate Development of CH5126766 (VS-6766), a RAF/MEK Inhibitor, in Combination with Defactinib, a FAK Inhibitor, for the Treatment of KRAS Mutant Solid Tumors Company Continues to Advance Development of Duvelisib for the Treatment of Relapsed/Refractory PTCL Strengthened Balance Sheet Through Private Placement Resulting in Anticipated Gross Proceeds of $100 Million; Projected Cash Runway into 4Q 2021
-
Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors
2/28/2020
Verastem, Inc. (NASDAQ: VSTM) (the “Company”), today announced that it has agreed to sell approximately 46.5 million shares of its common stock to certain institutional investors, including RA Capital Management, Vivo Capital, Venrock Healthcare Capital Partners, Farallon Capital Management, Acuta Capital, EcoR1 Capital LLC, Avidity Partners and Logos Capital.,
-
The company expects to decrease its operating expenses by about 40% this year compared to 2019.
-
Verastem Oncology Announces Dosing of First Patient in CSPC’s Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma
1/29/2020
Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), today announced that its partner CSPC Pharmaceutical Group Limited (HKEx: 1093) (CSPC), a leading pharmaceutical company in China, has dosed the first patient in a pivotal Chinese bridging study evaluating COPIKTRA
-
Biotechnological Breakthroughs Help Revamp the Fight Against Cancer
1/9/2020
Biotechnology plays an important role throughout various sectors by improving industry standards, services, and developing new products.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan. 6, 2020
1/6/2020
Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 110,963 shares of its common stock to eight new employees.
-
Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting
12/7/2019
Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial
-
Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award
11/13/2019
Verastem, Inc., announced that Andrei Shustov, M.D., Professor of Medicine and Hematology, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center and President and Founder of the T-Cell Leukemia and Lymphoma Foundation has been selected to receive the Company’s Innovation in Care Award.
-
Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048
11/12/2019
The exchange is expected to close on November 14, 2019, subject to customary closing conditions.
-
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
10/29/2019
Company Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY2019 Revenue Guidance
-
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress
10/23/2019
Verastem, Inc. announced that five posters highlighting clinical data for COPIKTRA™ will be presented at the Lymphoma & Myeloma 2019 International Congress taking place October 23-26, 2019, in New York City.
-
Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019
10/17/2019
Verastem, Inc. announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 p.m.
-
Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
10/7/2019
Verastem, Inc., announced that its partner Yakult Honsha Co., Ltd. has dosed the first patient in a Phase 1b Japanese bridging study evaluating COPIKTRA® in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following at least one prior therapy.